Ningbo Menovo Pharmaceutical Co., Ltd.
Simbolis: 603538.SS
SHH
14.58
CNYRinkos kaina šiandien
-165.8310
P/E santykis
-26.5330
PEG koeficientas
3.09B
MRK kapitalizacija
- 0.01%
DIV pajamingumas
Ningbo Menovo Pharmaceutical Co., Ltd. (603538-SS) Finansinės ataskaitos
Balansas
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 0 | 724.7 | 1009.3 | 793.2 | |||||||||||||
balance-sheet.row.short-term-investments | 0 | 268.6 | 217.4 | 371.4 | |||||||||||||
balance-sheet.row.net-receivables | 0 | 320.7 | 231.5 | 266.2 | |||||||||||||
balance-sheet.row.inventory | 0 | 612.6 | 594.4 | 579.7 | |||||||||||||
balance-sheet.row.other-current-assets | 0 | 50.3 | 59.2 | 63.4 | |||||||||||||
balance-sheet.row.total-current-assets | 0 | 1759.4 | 1894.4 | 1702.4 | |||||||||||||
balance-sheet.row.property-plant-equipment-net | 0 | 1900.3 | 1801.9 | 1614.7 | |||||||||||||
balance-sheet.row.goodwill | 0 | 0 | 0 | 22.7 | |||||||||||||
balance-sheet.row.intangible-assets | 0 | 206.2 | 172.5 | 201.7 | |||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 0 | 206.2 | 172.5 | 224.4 | |||||||||||||
balance-sheet.row.long-term-investments | 0 | 315.3 | 82.7 | -51.8 | |||||||||||||
balance-sheet.row.tax-assets | 0 | 42.7 | 123.1 | 33.3 | |||||||||||||
balance-sheet.row.other-non-current-assets | 0 | 199.6 | 344.8 | 478.5 | |||||||||||||
balance-sheet.row.total-non-current-assets | 0 | 2664.1 | 2525.1 | 2299.1 | |||||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | |||||||||||||
balance-sheet.row.total-assets | 0 | 4423.5 | 4419.5 | 4001.5 | |||||||||||||
balance-sheet.row.account-payables | 0 | 553.7 | 499.3 | 389.1 | |||||||||||||
balance-sheet.row.short-term-debt | 0 | 542.8 | 497 | 505 | |||||||||||||
balance-sheet.row.tax-payables | 0 | 25.5 | 72.1 | 34.6 | |||||||||||||
balance-sheet.row.long-term-debt-total | 0 | 759.6 | 705.6 | 755.3 | |||||||||||||
Deferred Revenue Non Current | 0 | 81.5 | 70.6 | 48.7 | |||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 0 | - | - | - | |||||||||||||
balance-sheet.row.other-current-liab | 0 | 2 | 171 | 3.9 | |||||||||||||
balance-sheet.row.total-non-current-liabilities | 0 | 859.6 | 884 | 876.2 | |||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | |||||||||||||
balance-sheet.row.capital-lease-obligations | 0 | 15.7 | 30.3 | 28 | |||||||||||||
balance-sheet.row.total-liab | 0 | 2237.8 | 2246.2 | 2023 | |||||||||||||
balance-sheet.row.preferred-stock | 0 | 36.3 | 0 | 0 | |||||||||||||
balance-sheet.row.common-stock | 0 | 213.4 | 213.4 | 151.3 | |||||||||||||
balance-sheet.row.retained-earnings | 0 | 1210.6 | 1234.3 | 937.4 | |||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 0 | 75.6 | 101.4 | 77.6 | |||||||||||||
balance-sheet.row.other-total-stockholders-equity | 0 | 560.4 | 535.9 | 585.2 | |||||||||||||
balance-sheet.row.total-stockholders-equity | 0 | 2096.3 | 2085 | 1751.5 | |||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 0 | 4423.5 | 4419.5 | 4001.5 | |||||||||||||
balance-sheet.row.minority-interest | 0 | 89.4 | 88.3 | 227 | |||||||||||||
balance-sheet.row.total-equity | 0 | 2185.7 | 2173.2 | 1978.5 | |||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 0 | - | - | - | |||||||||||||
Total Investments | 0 | 315.3 | 300.1 | 319.6 | |||||||||||||
balance-sheet.row.total-debt | 0 | 1302.5 | 1202.6 | 1260.4 | |||||||||||||
balance-sheet.row.net-debt | 0 | 846.4 | 410.7 | 838.6 |
Pinigų srautų ataskaita
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 0 | 367.6 | 158.1 | 173.1 | ||||||||||||
cash-flows.row.depreciation-and-amortization | 0 | 101.8 | 98.9 | 85 | ||||||||||||
cash-flows.row.deferred-income-tax | 0 | -40.2 | -21 | 18.4 | ||||||||||||
cash-flows.row.stock-based-compensation | 0 | 24.7 | 5.3 | 10.9 | ||||||||||||
cash-flows.row.change-in-working-capital | 0 | -85.4 | -62.2 | -2.8 | ||||||||||||
cash-flows.row.account-receivables | 0 | -213.6 | -50.9 | -28.2 | ||||||||||||
cash-flows.row.inventory | 0 | -183 | -124.7 | -83 | ||||||||||||
cash-flows.row.account-payables | 0 | 351.4 | 134.4 | 63.3 | ||||||||||||
cash-flows.row.other-working-capital | 0 | -40.2 | -21 | 45.1 | ||||||||||||
cash-flows.row.other-non-cash-items | 0 | -91.4 | 41.5 | -32.9 | ||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 0 | 0 | 0 | 0 | ||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | 0 | -571.6 | -529.9 | -311.7 | ||||||||||||
cash-flows.row.acquisitions-net | 0 | 487.9 | -47.1 | 0.5 | ||||||||||||
cash-flows.row.purchases-of-investments | 0 | -713.9 | -1640.5 | -865 | ||||||||||||
cash-flows.row.sales-maturities-of-investments | 0 | 902.5 | 1562.2 | 693.5 | ||||||||||||
cash-flows.row.other-investing-activites | 0 | -54.6 | 52 | 3.8 | ||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | 0 | 50.3 | -603.3 | -479 | ||||||||||||
cash-flows.row.debt-repayment | 0 | -749.5 | -788.1 | -802.5 | ||||||||||||
cash-flows.row.common-stock-issued | 0 | 0.1 | 0.2 | 0.5 | ||||||||||||
cash-flows.row.common-stock-repurchased | 0 | -0.1 | -0.2 | -0.5 | ||||||||||||
cash-flows.row.dividends-paid | 0 | -50 | -13.8 | -41 | ||||||||||||
cash-flows.row.other-financing-activites | 0 | 621.1 | 1385.1 | 981.9 | ||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 0 | -178.5 | 583.1 | 138.4 | ||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | 14.6 | -2.3 | -2 | ||||||||||||
cash-flows.row.net-change-in-cash | 0 | 163.4 | 198.2 | -91 | ||||||||||||
cash-flows.row.cash-at-end-of-period | 0 | 537 | 373.6 | 174.5 | ||||||||||||
cash-flows.row.cash-at-beginning-of-period | 0 | 373.6 | 175.4 | 265.5 | ||||||||||||
cash-flows.row.operating-cash-flow | 0 | 277 | 220.6 | 251.6 | ||||||||||||
cash-flows.row.capital-expenditure | 0 | -571.6 | -529.9 | -311.7 | ||||||||||||
cash-flows.row.free-cash-flow | 0 | -294.7 | -309.3 | -60.1 |
Pajamų ataskaitos eilutė
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 0 | 1216.5 | 1457 | 1258.1 | |||||||||||||
income-statement-row.row.cost-of-revenue | 0 | 840.9 | 872.8 | 788.9 | |||||||||||||
income-statement-row.row.gross-profit | 0 | 375.6 | 584.2 | 469.2 | |||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | |||||||||||||
income-statement-row.row.research-development | 0 | - | - | - | |||||||||||||
income-statement-row.row.selling-general-administrative | 0 | - | - | - | |||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||||
income-statement-row.row.other-expenses | 0 | -10.8 | 116.4 | 110.8 | |||||||||||||
income-statement-row.row.operating-expenses | 0 | 291.2 | 341.4 | 281 | |||||||||||||
income-statement-row.row.cost-and-expenses | 0 | 1132.1 | 1214.2 | 1069.9 | |||||||||||||
income-statement-row.row.interest-income | 0 | 5.5 | 5.7 | 2.2 | |||||||||||||
income-statement-row.row.interest-expense | 0 | 29.1 | 27.4 | 27.2 | |||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||||
income-statement-row.row.total-other-income-expensenet | 0 | -76.4 | -21.2 | -7.6 | |||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | |||||||||||||
income-statement-row.row.other-operating-expenses | 0 | -10.8 | 116.4 | 110.8 | |||||||||||||
income-statement-row.row.total-operating-expenses | 0 | -76.4 | -21.2 | -7.6 | |||||||||||||
income-statement-row.row.interest-expense | 0 | 29.1 | 27.4 | 27.2 | |||||||||||||
income-statement-row.row.depreciation-and-amortization | 0 | 118.5 | 128.3 | 124.1 | |||||||||||||
income-statement-row.row.ebitda-caps | 0 | - | - | - | |||||||||||||
income-statement-row.row.operating-income | 0 | 18.7 | 405.3 | 187.9 | |||||||||||||
income-statement-row.row.income-before-tax | 0 | 8 | 384.2 | 180.3 | |||||||||||||
income-statement-row.row.income-tax-expense | 0 | -8.2 | 16.5 | 22.2 | |||||||||||||
income-statement-row.row.net-income | 0 | 11.6 | 338.9 | 142.5 |
Dažnai užduodami klausimai
Kas yra Ningbo Menovo Pharmaceutical Co., Ltd. (603538.SS) bendras turtas?
Ningbo Menovo Pharmaceutical Co., Ltd. (603538.SS) bendras turtas yra 4423515920.000.
Kokios yra įmonės metinės pajamos?
Metinės pajamos yra N/A.
Kokia yra įmonės pelno marža?
Įmonės pelno marža yra 0.319.
Koks yra įmonės laisvųjų pinigų srautas?
Laisvųjų pinigų srautas yra -0.853.
Kokia yra įmonės grynojo pelno marža?
Grynojo pelno marža yra -0.014.
Kokios yra bendros įmonės pajamos?
Bendrosios pajamos yra -0.013.
Kas yra Ningbo Menovo Pharmaceutical Co., Ltd. (603538.SS) grynasis pelnas (grynosios pajamos)?
Grynasis pelnas (grynosios pajamos) yra 11585592.000.
Kokia yra bendra įmonės skola?
Bendra skola yra 1302458461.000.
Koks yra veiklos sąnaudų skaičius?
Veiklos sąnaudos yra 291175048.000.
Koks yra įmonės grynųjų pinigų skaičius?
Įmonės grynieji pinigai yra 0.000.